Metadoxine (MG01CI)

DRUG2 trials

Sponsors

Alcobra Ltd.

Conditions

ADHDADHD Predominantly Inattentive Type

Phase 2

Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

CompletedNCT01243242

Alcobra Ltd.ADHD

Start: 2011-02-28End: 2011-09-30Updated: 2012-04-20

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

CompletedNCT01685281

Alcobra Ltd.ADHD Predominantly Inattentive Type

Start: 2013-08-31End: 2013-12-31Updated: 2014-01-14

Related Papers

Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD.

2014-09-0110 citations

Efficacy of Metadoxine Extended Release in Patients With Predominantly Inattentive Subtype Attention-Deficit/Hyperactivity Disorder

Postgraduate Medicine2013-07-0117 citations

A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.

2012-12-0118 citations